Significance of Foxp3 Positive Regulatory T Cell and Tumor Infiltrating T Lymphocyte in Triple Negative Breast Cancer
暂无分享,去创建一个
H. Koo | B. Moon | M. Cho | S. Sung | K. Lee | W. Han | Harin Cheong | Hanna Kang
[1] J. Jung,et al. Clinicopathological Feature and Recurrence Pattern of Triple Negative Breast Cancer , 2010 .
[2] H. Koo,et al. Frequency of Intrahepatic FoxP3+ Regulatory T cells during the Natural Course of Chronic Hepatitis B: An Immunohistochemical Study Using Needle-Biopsied Liver Tissue , 2010 .
[3] K. Jang,et al. The Prognostic Significance of the Tumor-Infiltrating FoxP3-Positive Regulatory T Cells in Gastric Carcinoma , 2010 .
[4] Carsten Denkert,et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] H. Stein,et al. Regulatory (FOXP3+) T cells as target for immune therapy of cervical intraepithelial neoplasia and cervical cancer , 2009, Cancer science.
[6] S. Fox,et al. Immunomodulation of FOXP3+ Regulatory T Cells by the Aromatase Inhibitor Letrozole in Breast Cancer Patients , 2009, Clinical Cancer Research.
[7] I. Ellis,et al. Triple‐negative/basal‐like breast cancer: review , 2009, Pathology.
[8] B. Moon,et al. Metaplastic Squamous Carcinoma of the Breast: Clinicopathologic Analysis of 17 Cases , 2009 .
[9] K. Allison,et al. Immunosuppressive regulatory T cells are associated with aggressive breast cancer phenotypes: a potential therapeutic target , 2008, Modern Pathology.
[10] B. Chauffert,et al. Pathologic Complete Response to Neoadjuvant Chemotherapy of Breast Carcinoma Is Associated with the Disappearance of Tumor-Infiltrating Foxp3+ Regulatory T Cells , 2008, Clinical Cancer Research.
[11] A. Tutt,et al. Triple negative tumours: a critical review , 2007, Histopathology.
[12] T. Curiel,et al. Tregs and rethinking cancer immunotherapy. , 2007, The Journal of clinical investigation.
[13] Ian O Ellis,et al. Prognostic markers in triple‐negative breast cancer , 2007, Cancer.
[14] Stephen B Fox,et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Robert D. Schreiber,et al. Interferons, immunity and cancer immunoediting , 2006, Nature Reviews Immunology.
[16] C. Perou,et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.
[17] George Coukos,et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.
[18] G. Sakamoto,et al. Immunophenotype of lymphocytic infiltration in medullary carcinoma of the breast , 2004, Virchows Archiv.
[19] E. Schmitt,et al. The Regulatory T Cell Family: Distinct Subsets and their Interrelations 2 , 2003, The Journal of Immunology.
[20] R. Tibshirani,et al. Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[21] T. Nomura,et al. Control of Regulatory T Cell Development by the Transcription Factor Foxp3 , 2002 .
[22] R. Schreiber,et al. Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.
[23] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[24] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[25] T. Mak,et al. Immunologic Self-Tolerance Maintained by Cd25+Cd4+Regulatory T Cells Constitutively Expressing Cytotoxic T Lymphocyte–Associated Antigen 4 , 2000, The Journal of experimental medicine.
[26] C K Osborne,et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] M. Toda,et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. , 1995, Journal of immunology.
[28] F. Burnet. The concept of immunological surveillance. , 1970, Progress in experimental tumor research.